The Wall Street Journal posted an interesting story about a man who needed a drug to treat his ALS or Lou Gehrig's disease. He could not get the funding for a large scale trial to approve the drug. I empathize, completely! See that picture of the Hulk? That's me. I'm angry. You won't like me when I'm angry.

As a type 1 diabetic, my concern for improving the lives of people affected by diabetes involves preventing and reversing the complications associated with the disease. The American Diabetes Association states the same somewhere in their mission statement. Ok ADA, put MY money where YOUR 501(C)3 is!!

When I called the American Diabetes Association and shared my excitement for the C-peptide treatment in human trials (in Sweden) reversing type 1 diabetic complications - I was floored when I heard their response.

Allie B: Can the American Diabetes Association please encourage a big pharmaceutical company to sponsor these trials here in the United States? The results in Sweden have conclusively shown reversal of complications associated with type 1 diabetes.

Mat P at the American Diabetes Association: The topic of C-peptide is very sexy in scientific forums. BUT - we don't like to tell big pharmaceutical companies what to do with their money because we don't like them to tell us what to do with ours.

Allie B (in my head): WHAT THE F%^&*)(*&^%$F do you DO as an organization to improve the lives of people affected by diabetes if you are not going to push for trials to prevent and arrest complications associated with the disease?

I'm afraid the American Diabetes Association and I do not share the same goals any longer. It was a long marriage, over 21 years - but I want a divorce. The largest diabetic organization in the United States is not willing to assist in getting a trial underway to prevent and reverse complications that could affect 2 million type 1 diabetics and between 2 and 4 million type 2 diabetics injecting insulin (without C-Peptide).

I didn't feel this way until I realized how disconnected their perception of diabetes is from the reality of the disease. What do you think?

The scientists at University of Pennsylvania School of Medicine discovered that it is possible to regenerate damaged cells of the pancreas. Although the cells that revealed this discovery are not the beta cells of the pancreas, researchers believe that this research could find new ways to replenish the organs ability to produce insulin in diabetics.

The pancreas is made up of two compartments with different functions: the islet compartment of insulin-producing beta cells and the much larger exocrine compartment composed of duct cells and acinar cells that make and deliver enzymes to the intestine for digestion. Diabetes is caused by the failure of the beta cells to make insulin, whereas pancreatic cancer usually originates from the exocrine compartment. Under certain conditions in tissue culture, acinar cells can synthesize insulin as well as amylase, a digestion enzyme.

Evidence from this research is pointing to the beta cell itself as the most promising source for generating new beta cells. The focus of research is now shifting toward the direct stimulation of islet cell growth in live animals. In contrast, once acinar cells are removed from the organism and placed into culture, they may have greater potential to change into other cell types, including beta cells. As a result, Stoffers' animal model and technical approach is currently being used by other groups in the United States, Europe, and China to determine conditions under which acinar cells can take on the features of duct cells and beta cells.